Sreekanth Puttachary

Assistant Professor
Send an Email

Office: 541-737-0972

Magruder Hall

Magruder Hall 134B

700 SW 30th Street

700 SW 30th Street
Corvallis, OR 97331
2016 Post-Doc, Microglial activation due to organic dust inhalation, Biomedical Sciences, Iowa State University, Ames, IA. 2016 Post-Doc, Epilepsy project, Biomedical Sciences, Iowa State University, Ames, IA. 2012 Ph.D., Pharmacology (Electrophysiology)
Professional Affiliations: 
Society for Neuroscience (SFN) National Center for Faculty Development and Diversity (NCFDD) World Association for the Advancement of Veterinary Parasitology (WAAVP) Indian Society of Veterinary Pharmacology and Toxicology (ISVPT) Karnataka Veterinary Cou
Honors and Awards: 
Iowa State University “Teaching Excellence Award” for undergraduate teaching during the graduate program (Dec 2010). Iowa State University “Teaching Excellence Award” for Undergraduate teaching during the graduate program (May 2010). Indian Society of Vet

Profile Field Tabs

Affiliated with: 
Biomedical Sciences
OSU Main Campus
Faculty Type: 
Research/Career Interests: 

My laboratory focuses on developing novel drug targets to slow down/prevent the progression of epilepsy using rodent models. Epilepsy is a chronic neurological disorder characterized by the occurrence of spontaneous recurrent seizures that affects both humans and animals. People of all ages, gender, socio-economic background and demography are susceptible to this disease. In the US, nearly 2.4 million people are affected which costs $15.5 billion in annual medical expense along with a loss of productivity of patients. Globally, more than 50 million people (among them 80% of patients from developing countries) are affected and 200,000 new cases are being diagnosed each year. Currently available antiepileptic drugs (AEDs) provide a symptomatic relief by suppressing the seizures. These drugs are associated with side effects that affect patient’s performance in daily life. In addition, 1/3rd of patients worldwide don’t even respond to these AED medications (drug resistant epilepsy) leaving them without any effective treatment options.

Although many types of epilepsies (including genetic forms) are documented, epilepsies from acquired causes constitute the most (about 50%). Usually, these cases exhibit an episode of initial seizures that result from various causes such as head injuries or infection or prolonged fever (in infants) or exposure to toxic chemicals. However, the effects of first seizure episode may further continue by triggering a series of neurobiological changes (referred to as epileptogenesis) that slowly transforms a normal brain to an epileptic brain riddled with spontaneous recurrent seizures (referred to as established epilepsy). Our lab is interested to understand epileptogenesis in order to develop viable drug targets to either slow down or to prevent the progression of the disease.

Exciting anecdotal reports in human patients and a burgeoning research findings in rodent models of epilepsy reveal a hope that derivatives marijuana may provide a therapeutic potential in treating drug resistant epilepsies. Cannabidiol, a less psychoactive compound, acts as an agonist of presynaptic Gi/o protein coupled cannabinoid receptor-1 to reduce vesicular neurotransmitter release by interfering with calcium dynamics and excitability. My lab is focused on investigating the effect drugs that target the endocannabinoid system during epileptogenesis and to further validate their long-term impact on the disease progression. We use state of the art long-term continuous wireless video-EEG acquisition in chemo-convulsant rodent models of epilepsy along with brain slice electrophysiology, immunofluorescence and molecular biological techniques.

My Publications


Journal Article